BC Innovations | Aug 18, 2016
Emerging Company Profile

Negative thinking for brain cancer

Sapience Therapeutics Inc. is developing a dominant-negative form of the transcription factor ATF5 to target refractory glioblastoma without touching the surrounding tissue, taking advantage of the fact the brain stops expressing the protein in early...
BC Innovations | Jun 3, 2010
Distillery Therapeutics

Indication: Cancer

Cancer Brain cancer Activating transcription factor 5 (ATF5); cAMP responsive element binding protein 3-like 2 (CREB3L2) Studies in vitro and in mice suggest that inhibiting CREB3L2 could help treat glioblastoma. CREB3L2 is a regulator of...
Items per page:
1 - 2 of 2